Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Cash from Financing Activities (2020 - 2025)

Terns Pharmaceuticals filings provide 6 years of Cash from Financing Activities readings, the most recent being $743.1 million for Q4 2025.

  • Quarterly Cash from Financing Activities rose 244347.04% to $743.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $743.5 million through Dec 2025, up 353.37% year-over-year, with the annual reading at $743.5 million for FY2025, 353.37% up from the prior year.
  • Cash from Financing Activities hit $743.1 million in Q4 2025 for Terns Pharmaceuticals, up from $324000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $743.1 million in Q4 2025 and bottomed at -$1.6 million in Q2 2021.
  • Average Cash from Financing Activities over 5 years is $73.6 million, with a median of $489000.0 recorded in 2023.
  • The largest annual shift saw Cash from Financing Activities tumbled 109.42% in 2021 before it soared 816360.0% in 2024.
  • Terns Pharmaceuticals' Cash from Financing Activities stood at $16000.0 in 2021, then surged by 662212.5% to $106.0 million in 2022, then plummeted by 86.92% to $13.9 million in 2023, then plummeted by 97.81% to $304000.0 in 2024, then soared by 244347.04% to $743.1 million in 2025.
  • Per Business Quant, the three most recent readings for TERN's Cash from Financing Activities are $743.1 million (Q4 2025), $324000.0 (Q2 2025), and $68000.0 (Q1 2025).